Revista de neurologia · 2012
[Limits of conventional oral and transdermal medication in Parkinson's disease].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
García-Ruiz Pedro J, Luquin M Rosario
Аннотация
At the present time, we have effective and potent antiparkinsonian drugs available which allow patients to have an acceptable functional capacity during the early years of Parkinson's disease. Yet, as time goes by, motor and functional deterioration develop, partly due to the presence of motor and non-motor complications. The conventional medication is unable to provide an adequate response if the motor fluctuations are beyond 3-4 hours of duration. At this point, it is reasonable to consider other therapies; among them subcutaneous apomorphine injection must be taken into account due to its simplicity and efficacy and later on, subcutaneous apomorphine infusion. Apomorphine is a very effective and clearly underused drug in the treatment of advanced Parkinson's disease.
Предметные рубрики MeSH
Administration, CutaneousAdministration, OralAntiparkinson AgentsApomorphineCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsClinical Trials as TopicDopamine AgonistsDrug Therapy, CombinationEnzyme InhibitorsHalf-LifeHumansIndansInjections, SubcutaneousLevodopaMeta-Analysis as TopicMulticenter Studies as TopicParkinson Disease